Profile data is unavailable for this security.
About the company
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
- Revenue in USD (TTM)0.00
- Net income in USD-15.31m
- Incorporated2021
- Employees6.00
- LocationAllarity Therapeutics Inc24 School St., 2Nd FloorBOSTON 02108United StatesUSA
- Phone+1 (401) 426-4664
- Fax+1 (302) 655-5049
- Websitehttps://allarity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.28m | 1.00 | -- | 1.60 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 12.49m | 4.00 | -- | 4.02 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 12.98m | 17.00 | -- | 5.05 | -- | 3.09 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.03m | 6.00 | -- | 1.09 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 13.07m | 82.00 | -- | 0.3755 | -- | 1.40 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| BioCardia Inc | 0.00 | -8.54m | 13.16m | 17.00 | -- | 5.01 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 13.23m | 1.00 | -- | 1.00 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 13.25m | -- | -- | 0.1486 | -- | 5.25 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Inotiv Inc | 513.02m | -68.63m | 13.41m | 1.95k | -- | 0.0985 | -- | 0.0262 | -2.22 | -2.22 | 15.80 | 3.96 | 0.6609 | 12.27 | 6.76 | 263,765.60 | -8.84 | -18.23 | -15.66 | -23.64 | 23.58 | 26.43 | -13.38 | -27.50 | 0.2673 | -0.6134 | 0.75 | -- | 4.54 | 53.36 | 36.72 | -- | 21.79 | -- |
| TRON Group Inc | 1.01m | -549.47k | 13.46m | 50.00 | -- | -- | -- | 13.33 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 13.62m | 44.00 | -- | 0.9306 | -- | 120.45 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 13.74m | 7.00 | 0.0609 | 2.70 | -- | 4.83 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 13.76m | 360.00 | -- | -- | -- | 0.0095 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Private Advisor Group LLCas of 30 Sep 2025 | 278.95k | 1.74% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 171.80k | 1.07% |
| Geode Capital Management LLCas of 30 Sep 2025 | 151.93k | 0.95% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 137.60k | 0.86% |
| Capital Advisors, Inc. (Oklahoma)as of 31 Dec 2025 | 100.00k | 0.62% |
| Citadel Securities LLCas of 30 Sep 2025 | 94.14k | 0.59% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 74.91k | 0.47% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 66.19k | 0.41% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 43.63k | 0.27% |
| UBS Securities LLCas of 31 Dec 2025 | 26.52k | 0.17% |
